Ogrania is indicated for: neuropathic pain (with damage to the central / peripheral nervous system); epilepsy (as adjunctive therapy for partial seizures with / without secondary generalization); fibromyalgia; generalized anxiety disorder.
Ogrania composition and form of release
The active ingredient is pregabalin 75 mg.
Release form – capsules.
It is used for epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder.
The pharmaceutical product is intended for use in adult patients.
Ogrania is indicated for:
- neuropathic pain (with damage to the central / peripheral nervous system);
- epilepsy (as adjunctive therapy for partial seizures with / without secondary generalization);
- generalized anxiety disorder.
Not used in case of hypersensitivity to it.
This pharmaceutical product is not used for children.
Application during pregnancy and lactation
The tool is not recommended for use in pregnant women, unless the benefit to the woman clearly outweighs the potential threat to the fetus.
During the period of therapy with this pharmaceutical, the child should not be breast-fed.
Method of administration and dosage
The dose range for Ogrania is 150–600 mg / day. The dose should be divided into two or three doses.
For neuropathic pain, therapy is usually started at 150 mg / day in two divided doses. In some patients, the dose may be increased to 300 mg / day after a break of three to seven days. If necessary, after an additional seven-day interval, the dose of Ogrania may be increased to a maximum of 600 mg / day.
In epilepsy, therapy with Ogrania begins with 150 mg / day, the dose is divided into two or three doses. After the first week of using this pharmaceutical, the dose can be increased by the attending doctor to 300 mg / day. After another week, it is allowed to increase the dose of Ogrania to the maximum (600 mg / day).
In generalized anxiety disorder, the dose should be divided into two or three doses. It can be in the range of 150-600 mg / day, depending on the specific clinical case. The need to continue using this pharmaceutical product needs to be periodically reassessed.
It is necessary to stop the use of this drug for patients gradually, for at least seven days, regardless of the indications.
An overdose of a pharmaceutical product is characterized by excitement, confusion, drowsiness, anxiety. In addition, the development of a coma is possible.
In case of an overdose with this drug, general supportive measures are indicated. If necessary, the patient undergoes hemodialysis.
Most often, when using a pharmaceutical drug in patients, there are side effects such as increased appetite, dizziness, hot flashes, tremors, diplopia (double vision), confusion, conjunctivitis, ataxia, euphoric mood, arterial hypo- / hypertension, irritability, vomiting, deterioration memory, insomnia / drowsiness, dry mouth, decreased libido, flatulence, disorientation, gastroenteritis, poor coordination, constipation, paresthesia, dysarthria, impotence, impaired attention, erectile dysfunction, sedation, headache, imbalance, blurred vision, lethargy, drunkenness, peripheral edema, weight gain, increased fatigue.
Hypersensitivity reactions (allergic reactions, angioedema, etc.) may also occur.
Storage conditions and periods
Store capsules at temperatures below + 25 ° C.
The shelf life of the pharmaceutical product is two years.